Pfizer announced that data from a long-term relapse prevention study shows that adult patients receiving Pristiq (desvenlafaxine extended-release tablets) 50mg/day experienced statistically significant longer time to relapse over six months compared with placebo. The data show that the probability of relapse with Pristiq 50mg/day was 14.3% versus 30.2% with placebo at Month 6. The most common treatment emergent adverse effects in both groups were headache, dizziness and depression, with dizziness and depression occurring in approximately twice as many in the placebo group. A larger percentage of patients on placebo in the double-blind phase (8.3%) discontinued treatment due to adverse events compared with patients who continued on Pristiq (3.3%).
As MDD is prevalent for women going through the menopause transition, Pristiq was evaluated in an eight-week, multicenter, double-blind, placebo-controlled study of 434 peri- and post-menopausal women with MDD. Those receiving Pristiq 50mg/day achieved statistically significant reductions in the 17-item Hamilton Rating Scale for Depression (HAM-D17) total scores compared to those taking placebo (–9.9, –8.1; P=0.004).
In a third study, abrupt discontinuation of treatment with Pristiq 50mg/day resulted in no statistically significant difference in Discontinuation-Emergent Signs and Symptoms Scale (DESS) total scores compared to a one-week taper using 25mg/day. However, abrupt discontinuation of Pristiq 50mg/day was associated with a greater incidence (51.4%) of new-onset adverse events (AEs) in the double-blind phase compared with the one-week taper using 25mg/day (36.1%).
For more information call (800)438-1985 or visit www.pristiq.com.